XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.25.2

Balance Sheet Components | 6 Months Ended
--- | ---
Jun. 30, 2025
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Components | Balance Sheet Components Goodwill Goodwill was $773.3 million and $745.8 million as of June 30, 2025 and December 31, 2024, respectively. The changes in the carrying amounts of goodwill during the three and six months ended June 30, 2025 were due to foreign currency translation. The Company has not recorded any impairment related to goodwill. Intangible Assets, Net Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):
| June 30, 2025 |  | December 31, 2024 |  | Weighted Average Remaining Amortization Period (Years)
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |
Percepta product technology | $ | 16,000 |  |  | $ | (10,933) |  |  | $ | 5,067 |  |  | $ | 16,000 |  |  | $ | (10,400) |  |  | $ | 5,600 |  |  | 5
Prosigna product technology | 4,120 |  |  | (1,534) |  |  | 2,586 |  |  | 4,120 |  |  | (1,396) |  |  | 2,724 |  |  | 9
Decipher product technology | 97,300 |  |  | (38,815) |  |  | 58,485 |  |  | 90,000 |  |  | (34,234) |  |  | 55,766 |  |  | 7
Decipher trade names | 4,000 |  |  | (3,443) |  |  | 557 |  |  | 4,000 |  |  | (3,043) |  |  | 957 |  |  | 1
C2i developed technology | 25,300 |  |  | (2,389) |  |  | 22,911 |  |  | 25,300 |  |  | (1,546) |  |  | 23,754 |  |  | 14
Total finite-lived intangibles | 146,720 |  |  | (57,114) |  |  | 89,606 |  |  | 139,420 |  |  | (50,619) |  |  | 88,801 |  |  | 8.5
In-process research and development | 6,200 |  |  | — |  |  | 6,200 |  |  | 13,500 |  |  | — |  |  | 13,500 |  |  |
Total intangible assets | $ | 152,920 |  |  | $ | (57,114) |  |  | $ | 95,806 |  |  | $ | 152,920 |  |  | $ | (50,619) |  |  | $ | 102,301 |  |  |
Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized. Amortization expense of $3.3 million and $3.8 million was recognized for the three months ended June 30, 2025 and 2024, respectively, and an expense of $6.5 million and $7.4 million was recognized for the six months ended June 30, 2025 and 2024, respectively. The estimated future aggregate amortization expense as of June 30, 2025 is as follows (in thousands of dollars):
Year Ending December 31, | Amounts
2025 remainder of year | $ | 6,657 |
2026 | 12,672 |
2027 | 12,515 |
2028 | 12,515 |
2029 | 12,515 |
Thereafter | 32,732 |
Total | $ | 89,606 |
Supplies and Inventory Supplies consisted of lab supplies and reagents to be used in the performance of testing services. Inventory related to finished and semi-finished goods used in the assembly of diagnostic kits related to product sales as well as raw materials consumed in the contract manufacturing process. As of June 30, 2025 and December 31, 2024, supplies and inventory consisted of the following (in thousands of dollars):
| June 30, 2025 |  | December 31, 2024
Supplies | $ | 20,065 |  |  | $ | 17,876 |
Inventory | 4,955 |  |  | 3,874 |
Total supplies and inventory | $ | 25,020 |  |  | $ | 21,750 |
Impairment of Assets On July 16, 2025, the Marseille Commercial Court published a decision approving the divestiture of certain portions of the Company's French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, effective August 1, 2025. The remaining assets will be managed by the judicial administrator until such time that the Marseille Commercial Court appoints a judicial liquidator to solely initiate and manage liquidation proceedings. Effective August 1, 2025, the Company no longer has the power to control the financial and operating policies of Veracyte SAS. The Company assessed the associated assets as of June 30, 2025 for impairment and determined that the value of the remaining assets of Veracyte SAS, including accounts receivable; supplies and inventory; right-of-use assets; property, plant, and equipment; and other receivables were not recoverable. As a result, the Company recorded a $20.5 million non-cash impairment charge during the three months ended June 30, 2025, as detailed in the impairment of assets row of the condensed consolidated statement of operations. See Note 11, Subsequent Events, for more information regarding Veracyte SAS. Accrued Liabilities Accrued liabilities consisted of the following (in thousands of dollars):
| June 30, 2025 |  | December 31, 2024
Accrued compensation expenses | $ | 25,764 |  |  | $ | 30,595 |
Accrued other | 17,943 |  |  | 13,231 |
Total accrued liabilities | $ | 43,707 |  |  | $ | 43,826 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration